{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:17:58Z","timestamp":1783091878100,"version":"3.54.6"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007225","name":"Socialist Republic of Vietnam Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ijantimicag.2024.107326","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:55:25Z","timestamp":1726188925000},"page":"107326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetics and safety of colistin sulfate after single and multiple intravenous doses in healthy Chinese subjects"],"prefix":"10.1016","volume":"64","author":[{"given":"Xiaolan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beining","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2966-9149","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107326_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0002","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3390\/molecules25061340","article-title":"Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0003","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S1473-3099(18)30513-9","article-title":"Analysis of the clinical antibacterial and antituberculosis pipeline","volume":"19","author":"Theuretzbacher","year":"2019","journal-title":"Lancet Infect. Dis"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0004","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","article-title":"Rescuing the last-line polymyxins: achievements and challenges","volume":"73","author":"Nang","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1017488","article-title":"Antimicrobial susceptibility to polymyxin B and other comparators against Gram-negative bacteria isolated from bloodstream infections in China: results from CARVIS-NET program","volume":"13","author":"Xi","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s44280-023-00009-9","article-title":"Current status and trends of antimicrobial resistance among clinical isolates in China: a retrospective study of CHINET from 2018 to 2022","volume":"1","author":"Yang","year":"2023","journal-title":"One Health Adv"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-030-16373-0_3","article-title":"History, chemistry and antibacterial spectrum","volume":"1145","author":"Velkov","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0008","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/AAC.00035-06","article-title":"Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa","volume":"50","author":"Bergen","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0009","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-3-030-16373-0_15","article-title":"Clinical pharmacokinetics, pharmacodynamics and toxicodynamics of polymyxins: implications for therapeutic use","volume":"1145","author":"Nation","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/ciu213","article-title":"Colistin and polymyxin B: peas in a pod, or chalk and cheese?","volume":"59","author":"Nation","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0011","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1128\/AAC.03510-14","article-title":"Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients","volume":"58","author":"Boisson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0012","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0013","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/antibiotics11101440","article-title":"Combination regimens with colistin sulfate versus colistin sulfate monotherapy in the treatment of infections caused by Carbapenem-resistant gram-negative Bacilli","volume":"11","author":"Hao","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0014","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.21037\/atm-22-4959","article-title":"Clinical efficacy and nephrotoxicity of intravenous colistin sulfate in the treatment of carbapenem-resistant gram-negative bacterial infections: a retrospective cohort study","volume":"10","author":"Jin","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0015","article-title":"Efficacy and safety of polymyxin E sulfate in the treatment of critically ill patients with carbapenem-resistant organism infections","volume":"9","author":"Lu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0016","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2147\/IDR.S398930","article-title":"Adverse events and drug resistance in critically ill patients treated with colistimethate sodium: a review of the literature","volume":"16","author":"Ahumada Topete","year":"2023","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0017","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.21037\/jtd-23-336","article-title":"Efficacy and safety of colistin sulfate in the treatment of infections caused by carbapenem-resistant organisms: a multicenter retrospective cohort study","volume":"15","author":"Peng","year":"2023","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.967412","article-title":"Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients","volume":"13","author":"Xie","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0019","article-title":"Population pharmacokinetics of colistin sulfate in critically ill patients: exposure and clinical efficacy","volume":"13","author":"Yu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2471\/BLT.08.050955","article-title":"The Declaration of Helsinki and public health","volume":"86","author":"Williams","year":"2008","journal-title":"Bull. World Health Organ"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0021","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.01367-09","article-title":"Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry","volume":"54","author":"Gobin","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0022","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jpba.2016.02.045","article-title":"Development and validation of a UHPLC-MS\/MS assay for colistin methanesulphonate (CMS) and colistin in human plasma and urine using weak-cation exchange solid-phase extraction","volume":"124","author":"Zhao","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jssc.201000680","article-title":"Validation of a novel LC-MS\/MS method for the quantitation of colistin A and B in human plasma","volume":"34","author":"Dotsikas","year":"2011","journal-title":"J Sep Sci"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0024","first-page":"173","article-title":"Establishment of a robust LC-MS\/MS method for the determination of polymyxin E1 and E2 in human plasma","volume":"22","author":"Huang","year":"2022","journal-title":"Chin J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1021\/acs.jnatprod.6b01176","article-title":"Pharmacokinetics of the Individual Major Components of Polymyxin B and Colistin in Rats","volume":"80","author":"Sivanesan","year":"2017","journal-title":"J Nat Prod"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0026","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.47.5.1766-1770.2003","article-title":"Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration","volume":"47","author":"Li","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0027","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/jac\/dkr239","article-title":"Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09)","volume":"66","author":"Gales","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0028","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/bcp.14576","article-title":"Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions","volume":"87","author":"Yu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0029","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jinf.2021.01.006","article-title":"Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects","volume":"82","author":"Liu","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0030","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/dkh167","article-title":"Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate","volume":"53","author":"Li","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0031","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/clpt.2011.48","article-title":"Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers","volume":"89","author":"Couet","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0032","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0033","article-title":"Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency","volume":"61","author":"Thamlikitkul","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0034","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ijantimicag.2017.12.025","article-title":"Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses","volume":"51","author":"Zhao","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0035","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1185\/03007995.2011.626557","article-title":"Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects","volume":"27","author":"Mizuyachi","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0036","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, 2024. http:\/\/www.eucast.org."},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0037","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1128\/AAC.00119-11","article-title":"In vitro potency of various polymyxin B components","volume":"55","author":"Tam","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0038","doi-asserted-by":"crossref","first-page":"7823","DOI":"10.1128\/AAC.01021-15","article-title":"Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination","volume":"59","author":"Kassamali","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107326_bib0039","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41467-022-29234-3","article-title":"A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens","volume":"13","author":"Roberts","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.ijantimicag.2024.107326_bib0040","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1128\/AAC.06426-11","article-title":"Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T02:11:22Z","timestamp":1732759882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924002425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0924857924002425"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107326","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and safety of colistin sulfate after single and multiple intravenous doses in healthy Chinese subjects","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107326"}}